Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses the hot topics in bladder cancer at ESMO 2022, including potential novel biomarkers and the results from Cohort K of the EV-103 trial (NCT03288545). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Do you know the signs of bladder cancer?

Dr. Bivalacqua discusses how muscle invasive bladder cancer is staged and the standards of care based on the diagnosis.

A one-time chemotherapy treatment is changing the game for bladder cancer patients and dropping the recurrence rate by almost 50 percent.

Christiaan De Jong, MD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses the findings of a study which performed transcriptome sequencing on samples from patients with T1 high-grade bladder cancer who had been treated with Bacillus Calmette-Guérin (BCG) with the goal of identifying molecular predictors of BCG failure. Three new molecular subtypes were identified by mRNA consensus clustering: BCG1, BCG2 and BCG3. Patients with BCG3 tumors had a worse progression-free survival (PFS) and high-grade recurrence-free survival in comparison to patients with BCG1 and BCG2 tumors. Patients with BCG1 tumors demonstrated a favorable PFS. It was also found that 67% of post-BCG tumor recurrences were BCG3 tumors. Overall, Dr De Jong reports that these insights can be used to improve clinical risk stratification of patients to receive BCG therapy versus early radical cystectomy, and talks on recent research which aims to validate this risk stratification model. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.

Part 1 of 4 What I Wish I Had Known When I was First Diagnosed with Bladder Cancer: Muscle Invasive Bladder Cancer.

Join Drs. Alicia Morgans and Josh Meeks and Patient Advocates Darrell Nakagawa and Ann Mardon to talk about what they wish they had known when they were first diagnosed.

Daniel J. George, MD, discusses variables that affect patients’ eligibility to be treated with cisplatin-based chemotherapy and reviews patient selection criteria for frontline gemcitabine and carboplatin.